Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
Articolo
Data di Pubblicazione:
2011
Citazione:
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG) / Conconi, A; Martinelli, G; Lopez Guillermo, A; Zinzani, P. L; Ferreri, A. J. M; Rigacci, L; Devizzi, L; Vitolo, U; Luminari, Stefano; Cavalli, F; Zucca, E.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 22:3(2011), pp. 689-695. [10.1093/annonc/mdq416]
Abstract:
The nuclear factor-kappa B activation in mucosa-associated lymphoid tissue (MALT) lymphoma pathogenesis provided the rationale for the evaluation of bortezomib in this malignancy.
Tipologia CRIS:
Articolo su rivista
Keywords:
Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Pyrazines; Recurrence; Treatment Failure; Treatment Outcome
Elenco autori:
Conconi, A; Martinelli, G; Lopez Guillermo, A; Zinzani, P. L; Ferreri, A. J. M; Rigacci, L; Devizzi, L; Vitolo, U; Luminari, Stefano; Cavalli, F; Zucca, E.
Link alla scheda completa:
Pubblicato in: